The short version of Aib substitution fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-06-21. Anything still debated is marked as such rather than presented as settled.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide, GLP-1 receptor agonist | Not a small molecule |
| Backbone substitutions | Non-natural residue at position 8, arginine at position 34 | Slows enzymatic cleavage |
| Side chain | C18 fatty diacid with PEG linker | Enables albumin binding |
| Approximate molecular mass | 4114 Da | Varies slightly with salt form |
| Reported half-life | About one week | Longer than native GLP-1 by orders of magnitude |
GLP-1 receptors are expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises cyclic AMP, enhances glucose-dependent insulin secretion, and suppresses glucagon release when blood glucose is high. Effects on gastric emptying and on hypothalamic appetite circuits reduce energy intake. Because insulin release remains glucose-dependent, the risk of hypoglycemia is low when the drug is used alone. The precise contribution of each pathway to body weight change in humans remains an area of active investigation.
Clinical studies of semaglutide generally measure glycated hemoglobin, fasting plasma glucose, body weight, and composite cardiovascular endpoints. The SUSTAIN program enrolled adults with type 2 diabetes, while the STEP program focused on obesity without diabetes. Administration follows a stepwise escalation schedule designed to limit gastrointestinal effects during the first weeks. Reported outcomes include mean percentage weight change, the proportion of participants reaching defined weight-loss thresholds, and rates of nausea, vomiting, and diarrhea. Long-term data on durability after treatment stops are still limited and remain a topic of ongoing research.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Solid peptide material is generally kept at reduced temperature to limit degradation. Short-term storage at 2 to 8 degrees Celsius is common, while longer archival storage at minus 20 degrees Celsius or below is typical for lyophilised powder. Vials should remain sealed and protected from light, because ultraviolet exposure can oxidise susceptible residues. Repeated freeze-thaw cycles are avoided, as they promote aggregation and loss of soluble material. Solutions are less stable than solids and are usually prepared close to the time of use.
Reversed-phase high-performance liquid chromatography is widely used to assess purity and to separate the parent peptide from related substances. Mass spectrometry confirms identity and can resolve modifications that differ by a few daltons. Size-exclusion chromatography detects dimers and higher aggregates, which are relevant to both stability and immunogenicity questions. Peptide mapping with enzymatic digestion locates specific modifications along the sequence. Circular dichroism provides a secondary-structure profile, although it gives limited information about local conformational changes.
Quality control for peptide material focuses on identity, purity, content and the profile of impurities. Common degradants include deamidated and oxidised forms, plus aggregates formed during storage or handling. Forced degradation studies under heat, light, acid and peroxide help define which conditions accelerate change and which analytical methods detect it. Limits for individual impurities are set by pharmacopoeial monographs or manufacturer specifications. How much a given impurity affects biological activity is often uncertain, and conclusions may depend on the assay used.
Bis(trimethylsilyl)acetamide (BSA) is an organosilicon compound with the formula MeC(OSiMe3)NSiMe3 (Me = CH3). It is a colorless liquid that is soluble in diverse organic solvents, but reacts rapidly with moisture and solvents containing OH and NH groups. It is used in analytical chemistry to increase the volatility of analytes, e.g., for gas chromatography. It is also used to introduce the trimethylsilyl protecting group in organic synthesis. A related reagent is N,O-bis(trimethylsilyl)trifluoroacetamide (BSTFA).
Hird continued to be an outstanding performer in his utility role when fit, but age was forcing him to miss games through injury with increasing frequency. He suffered broken ribs and a calf strain during his 200th and 250th games, respectively.
Lipid-based nanoparticles are very small spherical particles composed of lipids. They are a novel pharmaceutical drug delivery system (part of nanoparticle drug delivery), and a novel pharmaceutical formulation. There are many subclasses of lipid-based nanoparticles such as: lipid nanoparticles (LNPs), solid lipid nanoparticles (SLNs), and nanostructured lipid carriers (NLCs). Sometimes the term "LNP" describes all lipid-based nanoparticles. In specific applications, LNPs describe a specific type of lipid-based nanoparticle, such as the LNPs used for the mRNA vaccine. Using LNPs for drug delivery was first approved in 2018 for the siRNA drug Onpattro. LNPs became more widely known late in 2020, as some COVID-19 vaccines that use RNA vaccine technology coat the fragile mRNA strands with PEGylated lipid nanoparticles as their delivery vehicle (including both the Moderna and the Pfizer–BioNTech COVID-19 vaccines).
Icaridin (Insect repellent) SSRIs (selective serotonin reuptake inhibitors) Paroxetine Stimulants and nootropics: Methylphenidate Ethylphenidate Pipradrol Desoxypipradrol Histamine 1 (H1) receptor antagonists/inverse agonists: Loratadine Histamine 3 (H3) receptor antagonists/inverse agonists: Pitolisant SERM (selective estrogen receptor modulators) Raloxifene Vasodilators Minoxidil Antipsychotic medications: Droperidol Haloperidol Melperone Mesoridazine Risperidone Thioridazine Opioids: Dipipanone Fentanyl and analogs Loperamide Pethidine (meperidine) Prodine Arylcyclohexylamines: PCP and analogs anticholinergic chemical weapons Ditran N-Methyl-3-piperidyl benzilate (JB-336, BZ) Piperidine is also commonly used in chemical degradation reactions, such as the sequencing of DNA in the cleavage of particular modified nucleotides. Piperidine is also commonly used as a base for the deprotection of Fmoc-amino acids used in solid-phase peptide synthesis. Piperidine is listed as a Table II precursor under the United Nations Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances due to its use (peaking in the 1970s) in the clandestine manufacture of phencyclidine.
=== Pharmacokinetics === The conversion of codeine to morphine occurs in the liver and is catalyzed by the cytochrome P450 enzyme CYP2D6. CYP3A4 produces norcodeine, and UGT2B7 conjugates codeine, norcodeine, and morphine to the corresponding 3- and 6-glucuronides. Srinivasan, Wielbo, and Tebbett speculate that codeine-6-glucuronide is responsible for a large percentage of the analgesia of codeine, and thus these patients should experience some analgesia. CYP2D6 converts codeine into morphine, which then undergoes glucuronidation. Life-threatening intoxication, including respiratory depression requiring intubation, can develop over a matter of days in patients who have multiple functional alleles of CYP2D6, resulting in ultrarapid metabolism of opioids such as codeine into morphine. Studies on codeine's analgesic effect are consistent with the idea that metabolism by CYP2D6 to morphine is important, but some studies show no major differences between those who are poor metabolizers and extensive metabolizers. Evidence supporting the hypothesis that ultrarapid metabolizers may get greater analgesia from codeine due to increased morphine formation is limited to case reports. Due to the increased metabolism of codeine to morphine, ultrarapid metabolizers (those possessing more than two functional copies of the CYP2D6 allele) are at increased risk of adverse drug effects related to morphine toxicity.
Sources: en.wikipedia.org
== Adverse effects == Depolarizing drug Succinylcholine: Succinylcholine presents several undesirable side effects which affect its application as it interacts with both muscarinic and nicotinic receptors, due to its acetylcholine-mimicking properties. Firstly, hyperkalemia is the most seen adverse effect of succinylcholine due to its stimulatory effect of the drug on skeletal muscles. This results in an increase in serum potassium levels as high as 0.5 mEq/L. This increase is clinically insignificant in normal patients but can be detrimental for patients with predisposed hyperkalemia caused by up-regulation of post-junctional acetylcholine receptors. Therefore, succinylcholine use is contraindicated for this category of patients. Further consideration is also required for patients with chronically elevated potassium or traumatic injuries, as there is a high probability of acute hyperkalemia which can lead to dysrhythmia or death. Secondly, succinylcholine causes the activation of muscarinic receptors in the SA node, causing bradycardia. This effect is especially highlighted in use with patients with high vagal tone (traumatic or young patients). In adults with a normal vagal tone, bradycardia has only been reported on repeated incremental dosages of succinylcholine. Anticholinergic drugs such as atropine and glycopyrrolate can be used as secondary therapy in treating or prophylaxis of bradycardia.
British soldiers were fed freshly cooked meals when in camp or barracks and troops on deployment could eat meals from field kitchens whenever possible, but soldiers were also reliant on rations. The British Army issued 24-hour rations intended to sustain troops until composite rations and fresh food could be supplied by field kitchens. An example of such a 24 hour ration pack issued to British and Commonwealth soldiers contained the following: 10 biscuits, two oatmeal blocks, milk, sugar, and tea blocks, four tablets of sugar, one block of meat, two pieces of raisin chocolate and one piece of plain chocolate, boiled sweets, one packet of salt, meat extract tablets, two packets of chewing gum, and four pieces of latrine paper. Composite rations, known as "compo" rations or 14-man rations, were designed to sustain 14 men for one day and came in wooden crates. A composite ration crate would include meats such as bully beef, sausage, spam, steak and kidney pudding, fruit pudding, treacle pudding, soup, beans, cheese, biscuits, jam, margarine, tea, powdered milk, and sugar. The composite ration was introduced at the end of the North African campaign to alleviate nutritional problems caused by Commonwealth rations in North African being largely bully beef and biscuits. Prior to its introduction tinned fruit had been introduced to improve nutrition. On the home front in Britain, mobile canteens were operated to provide Home Guard and civil defence authorities with hot food and fresh tea. A similar system applied to Canadian soldiers.
Surfactants play an important role in droplet-based microfluidics. The main purpose of using a surfactant is to reduce the interfacial tension between the dispersed phase (droplet phase, typically aqueous) and continuous phase (carrier liquid, typically oil) by adsorbing at interfaces and preventing droplets from coalescing with each other, therefore stabilizing the droplets in a stable emulsion state, which allows for longer storage times in delay-lines, reservoirs, or vials. Without using surfactants, the unstable emulsions will eventually evolve into separate phases to reduce the overall energy of the system. Surface chemistry cannot be ignored in microfluidics as the interfacial tension becomes a major consideration among microscale droplets. Linas Mazutis and Andrew D. Griffiths presented a method that used surfactants to achieve a selective and highly controllable coalescence without external manipulation. They manipulate the contact time and the interfacial surfactant coverage of a drop pair to control droplet fusion. The larger the difference percentage of the interfacial surfactant coverage between two droplets, the less likely coalescence will occur. This method allowed researchers to add reagents to droplets in a different way and further study the emulsification.
Severe Early-Onset Cardiac and Multiorgan Failure Form: symptoms appear within days of birth and include hypertrophic/dilated cardiomyopathy, fluid around heart (pericardial effusion), heart rhythm problems (arrhythmias), hepatomegaly and occasional intermittent hypoglycemia Hepatic or Hypoketotic Hypoglycemic Form: typically appears in early childhood with hypoketotic hypoglycemia Later-Onset Episodic Myopathic Form: presents with muscle breakdown after exercise (intermittent rhabdomyolysis), muscle cramps and pain, exercise intolerance and low blood sugar Treatments
Sources: en.wikipedia.org
For some wine styles, such as light, fruity wines or for low-acid wines from warm climates, malolactic fermentation is not desired. Winemakers can take several steps to prevent MLF from taking place, including:
== Design and manufacture == The design and manufacture of PMPs involves biomaterial selection, nanoparticle engineering, surface functionalization, and scalable production techniques to mimic the structure, function, and biomechanical properties of native platelets. One such design is a nanohair decorated microsphere made by a research group. These are small particles created from a combination of polystyrene, polyaniline (PANi), and epithelial cell adhesion molecule (EpCAM) antibodies that bind to circulating tumor cells. These spheres are designed to have a 1μm diameter created with the polystyrene molecules where the inner layer is hydrophilic to surround the core. The PANi is used to create nanohairs that simulate the natural aggregation of platelets. These nanohairs are attached to the surface of the polystyrene nanoparticles and range in length from 100 to 800 nm. The EpCAM antibodies are also attached to the nanospheres and are capable of binding to the EpCAM of circulating tumor cells in order to capture and remove them from circulation.
The molecular mechanism behind the formation of these tumors is not well understood, likely due to their low prevalence. Currently, no mutations have been identified in association with thyrotroph adenomas. In the presence of other pituitary tumors, the thyrotropic cells are unaffected.
Sources: en.wikipedia.org
Native GLP-1 is degraded within minutes by circulating enzymes. The synthetic version carries substitutions at positions that block enzymatic cleavage, plus a fatty acid side chain that promotes albumin binding. These two changes together extend circulation time from minutes to roughly a week.
Albumin binding keeps a large fraction of the compound in a slowly released reservoir within the bloodstream. Plasma levels decline gradually rather than falling sharply after each administration. That profile supports dosing intervals measured in days instead of hours.
The active peptide sequence is the same in both formats. The oral version adds an absorption enhancer that is not present in the injected solution. Differences in excipients and formulation affect uptake rather than the identity of the active molecule.
Native GLP-1 is a short-lived peptide cleared within one to two minutes by dipeptidyl peptidase-4 and related enzymes. Semaglutide keeps the receptor-binding backbone but adds substitutions and a lipid chain. These changes block the main cleavage site and allow reversible albumin binding, extending the half-life to roughly 165 hours.